CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Guided Solutions

Guided Solutions connects with clients at every stage of their life, from renters insurance for their first apartment, home insurance for a newly purchased home, to running a business, all the way through their Medicare needs.

Texas Champion Bank

Financial Serivices Company

Zea Biosciences

ZEA manufactures plant biologics for pharmaceutical uses providing wellness to the world. At ZEA, we are uprooting medicine by growing plants and using our proprietary technology to produce medicinal plant products and we offer superior data analytics in what is a $400 billion dollar market.

MedVet

MedVet is the leading veterinarian owned and led network of specialty and emergency hospitals dedicated to delivering exceptional care and a deeply supportive experience to pets and their loving families, referring veterinarians, and team members. For more than 35 years, MedVets empathetic, insightful, and driven team of expert caregivers has helped the organization grow to be the preferred choice for high quality, compassionate care, proudly serving more than 500,000 patients each year in communities throughout the United States. Our caregivers are deeply committed to MedVets mission of Leading Specialty Healthcare for Pets and our driven by our core values of Teamwork, Leadership, and Compassion. Visit www.medvet.com for further information and to view employment opportunities at MedVet. MedVet is an Equal Opportunity Employer.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.